Equity Profile

BNTX

BioNTech SE

Health CareBiotechnology$22.8B

Aug4Tue

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

BioNTech SE is a biotechnology company focused on developing immunotherapies for cancer and infectious diseases. With a market cap of $23 billion, it gained significant attention for its role in developing a COVID-19 vaccine, highlighting its innovative approach in the health care sector.

Key Metrics to Watch

EPS

Earnings per share (EPS) will indicate the company's profitability and how well it is managing costs.

N/A

Revenue

Revenue figures will provide insight into the demand for BioNTech's products and overall business health.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

BNTX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+9.61%

Avg Stock Reaction

-4.09%

Last Quarter Recap

In Q1 2026, BioNTech reported an EPS of -$2.28, which was better than the expected -$2.52, leading to a slight stock decline of 3.88% the following day. The company continues to face challenges in achieving profitability amidst fluctuating revenues.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic about BioNTech's upcoming earnings report, particularly in light of its recent performance surprises. However, the lack of analyst estimates adds uncertainty to expectations.

Bull Case

If BioNTech can demonstrate improved cost management and higher-than-expected revenue, it could signal a turnaround, boosting investor confidence.

Bear Case

Conversely, if the company reports larger losses or disappointing revenue, it could further erode investor trust and lead to a significant stock drop.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS figure be for Q2 2026, and how does it compare to previous quarters?

Given the company's recent history of EPS surprises, this figure will be crucial in determining market sentiment.

What is the revenue outlook for BioNTech's key products?

Revenue trends will be closely monitored to assess demand and the company's ability to recover from recent losses.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating BioNTech's potential for a strong recovery, given its recent cost management improvements and product pipeline.

Supporting Evidence

The company's recent EPS surprise indicates better-than-expected cost control.

Options pricing suggests traders are anticipating significant movement, reflecting uncertainty that could swing positively.

Recent insider selling may not reflect long-term confidence in the company's recovery potential.

Key Risk

If the revenue figure exceeds $500 million, it could challenge the current cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results are critical as they will indicate whether BioNTech can stabilize its financial performance after a series of disappointing earnings.

Bull Confirmed If

A revenue figure exceeding $500 million would confirm the bull case and suggest a recovery in demand.

Bear Confirmed If

An EPS loss greater than -$2.50 would reinforce the bear case and raise concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±10.69%

Historical Avg

±4.7%

Pricing rich

The options market is pricing in a significant move of about 10.69%, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±10.7% while BNTX has averaged ±4.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

37.4%

Calls (22K)P/C Ratio: 0.41Puts (26K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BioNTech beats expectations, history suggests a potential average one-day move of +2.09%, which would confirm a positive trend.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction, reflecting ongoing investor caution.

Miss

A miss could lead to a decline of around -7.43% based on historical patterns, further impacting investor confidence.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the revenue generated from COVID-19 vaccine sales.
2Any updates on new product developments or clinical trials.
3Management's commentary on cost management strategies.
4Insights into market demand for BioNTech's therapies.
5Future guidance on profitability timelines.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share (EPS) will indicate the company's profitability and how well it is managing costs.

N/A

Revenue

Revenue figures will provide insight into the demand for BioNTech's products and overall business health.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

BNTX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

63%

Avg EPS Surprise

+9.61%

Avg Stock Reaction

-4.09%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If BioNTech can demonstrate improved cost management and higher-than-expected revenue, it could signal a turnaround, boosting investor confidence.

Bear Case

Conversely, if the company reports larger losses or disappointing revenue, it could further erode investor trust and lead to a significant stock drop.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS figure be for Q2 2026, and how does it compare to previous quarters?

Given the company's recent history of EPS surprises, this figure will be crucial in determining market sentiment.

What is the revenue outlook for BioNTech's key products?

Revenue trends will be closely monitored to assess demand and the company's ability to recover from recent losses.

Edge

What the Street Is Missing

Why consensus could be wrong

The market may be underestimating BioNTech's potential for a strong recovery, given its recent cost management improvements and product pipeline.

Supporting Evidence

The company's recent EPS surprise indicates better-than-expected cost control.

Options pricing suggests traders are anticipating significant movement, reflecting uncertainty that could swing positively.

Recent insider selling may not reflect long-term confidence in the company's recovery potential.

Key Risk

If the revenue figure exceeds $500 million, it could challenge the current cautious consensus.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results are critical as they will indicate whether BioNTech can stabilize its financial performance after a series of disappointing earnings.

Bull Confirmed If

A revenue figure exceeding $500 million would confirm the bull case and suggest a recovery in demand.

Bear Confirmed If

An EPS loss greater than -$2.50 would reinforce the bear case and raise concerns about the company's financial health.

Pre-Earnings Positioning

Options Market

Implied Move

±10.69%

Historical Avg

±4.7%

Pricing rich

The options market is pricing in a significant move of about 10.69%, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±10.7% while BNTX has averaged ±4.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

37.4%

Calls (22K)P/C Ratio: 0.41Puts (26K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BioNTech beats expectations, history suggests a potential average one-day move of +2.09%, which would confirm a positive trend.

In-Line / Cautious

If results are in line with expectations, the stock may see a muted reaction, reflecting ongoing investor caution.

Miss

A miss could lead to a decline of around -7.43% based on historical patterns, further impacting investor confidence.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the revenue generated from COVID-19 vaccine sales.
2Any updates on new product developments or clinical trials.
3Management's commentary on cost management strategies.
4Insights into market demand for BioNTech's therapies.
5Future guidance on profitability timelines.